Home
Login
Help
Search this site:
Registered Trials
By recruitment status
By sponsor
By registration date
Advanced search for trials
Registration process
To register a trial
Sponsor registration form
RPCEC trial registration Data Set
To update a registered trial
To disclosure the results of registered trial
Home
|
Efficacy and safety of the Dermatological Soap with ozonated sunflower oil (AGO), or with sulfur, or with sulfur+AGO and Cream with AGO in patients with Scabies.
View current
Revisions
List all revisions
View
Compare to current
16 April 2024 - 12:45pm
by Gladys
19 December 2025 - 2:20pm
by Gladys
Changes to
Record Verification Date
-
2024
/
04
/
16
+
2025
/
12
/
19
Changes to
Next update date
-
2025
/
04
/
16
+
2026
/
12
/
19
Revision of 19 December 2025 - 2:20pm:
Efficacy and safety of the Dermatological Soap with ozonated sunflower oil (AGO), or with sulfur, or with sulfur+AGO and Cream with AGO in patients with Scabies.
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Acronym of Public Title:
AGO-ESC
Scientific title:
Evaluation of the efficacy and safety of Dermatological Soap with AGO, or with sulfur, or with sulfur+AGO and Cream with AGO in patients with Scabies.
Acronym of Scientific Title:
AGO-ESCABIOSIS
Secondary indentifying numbers:
AGO-ESC-01
Issuing authority of the secondary identifying numbers:
National Centre for Scientific Research (CNIC)
Primary sponsor:
National Centre for Scientific Research (CNIC)
Secondary sponsor:
Not applicable
Source(s) of monetary or material support:
Ministry of Science , Technology and Enviroment (CITMA)
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Only approved by Ethics Committees
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Thuyen
Last name:
Fong Fernandez
Medical Specialty :
Second Degree Specialist in Dermatology
Affiliation:
10 de Octubre Clinical Surgical Teaching Hospital
Postal address:
10 de Octubre No. 130 /Agua Dulce y Serafines, Cerro
City:
Havana
Country:
Cuba
Zip Code:
10300
Telephone:
+53-52655476
Email address:
thuyen.fong@infomed.sld.cu
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Havana, "General Peraza" Elderly House, Thuyen Fong Fernandez, MD. Second Degree specialist in Dermatology
Havana, "28 de Enero" Elderly House, Thuyen Fong Fernandez, MD. Second Degree specialist in Dermatology
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Pending
Date of first enrollment:
02/09/2024
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Scabies
Intervention(s):
Group 1 (Experimental): Dermatological soap with AGO + Cream with AGO. The soap will be used for daily bathing in the afternon and then applyng the cream, topically, from the neck down, scalp and ears for 21 days. Group 2 (Control): Dermatological soap with sulfur + Cream with AGO. The soap will be used for daily bathing in the afternon and then applyng the cream, topically, from the neck down, scalp and ears for 21 days. Group 3 (Experimental): Dermatological soap with sulfur-AGO + Cream with AGO. The soap will be used for daily bathing in the afternon and then applyng the cream, topically, from the neck down, scalp and ears for 21 days. AGO: Ozonized sunflower oil
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
1. Cure clinical (absence of itching and skin lesions ) or clinical improvement (improvement of itching and skin lesions). Measurement time: 7, 14 and 21 days of treatment. 2. Negativization of Dermatoscopy (Positive, Negative). Measurement time: 21 days of treatment.
Key secondary outcomes:
1. EASI Scale (Eczema Area and Severity Index). Measurement time: At baseline and, 7, 14 and 21 days of treatment. 2. VAS Scale (Visual analogical scale). Measurement time: At baseline and, 7, 14 and 21 days of treatment. 3. Quality of Life Questionnaire (EuroQol). Measurement time: At baseline and, 7, 14 and 21 days of treatment.
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
19 years
Maximum age:
None
Inclusion criteria:
Patients with confirmed scabies, of both sexes, 19 years or older, who present itching mainly at night and the presence of skin lesions, who agree to participate in the study after signing their informed consent.
Exclusion criteria:
Patients with: 1. Skin lesions with added infection 2. Known hypersensitivity to the products to be used 3. Other skin lesions already diagnosed 4. Moderate-severe cognitive disorders
Type of population:
Adults
Type of participant:
Patients
Study design
Section to complete information about the characteristics of the study design.
Type study:
Interventional
Purpose:
Treatment
Allocation:
Randomized controlled trial
Masking:
Open
Control group:
Active
Study design:
Parallel
Phase:
N/A
Target sample size:
75
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Thuyen
Last Name:
Fong Fernandez
Specialty:
Second degree specialist in Dermatology
Affiliation:
10 de Octubre Clinical Surgical Teaching Hospital
Postal Address:
10 de Octubre No. 130 / Agua Dulce y Serafines, Cerro
City:
Havana
Country:
Cuba
Zip Code:
10300
Telephone:
+53-52655476
Email :
thuyen.fong@infomed.sld.cu
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Julio
Middle Name:
Cesar
Last Name:
Fernandez Travieso
Specialty:
Dr. in Pharmaceutical Sciences
Affiliation:
National Centre for Scientific Research (CNIC)
Postal Address:
25 avenue and 158 stree, Cubanacan, Playa
City:
Havana
Country:
Cuba
Zip Code:
11300
Telephone:
+53-59958136
Email :
julio.fernandez@cnic.cu
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
10 de Octubre Clinical Surgical Teaching Hospital
Status of evaluation:
Approved
Status of evaluation date of Ethic Committee:
30/11/2023
Postal address of Ethic Committee :
10 de Octubre No. 130 e/ Agua Dulce y Serafines. Cerro, ZC:10300, La Habana. Cuba
Telephone:
+53-78252292
Email:
manuel.hernandez@infomed.sld.cu
About study completion
Section to complete the data related to the study completion.
Study completion date:
25/11/2024
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000439
Date of Registration in Primary Registry:
16/04/2024
Record Verification Date:
2025/12/19
Next update date:
2026/12/19
Link to the spanish version:
Click here
About the RPCEC
Structure and governance
Policy
Publications
Awards
Communications
News
Useful resources
Fundamentals of the registry
References of clinical trials
Cuban regulations
Other registries
International Clinical Trials Registry Platform